By Application
Hot products 
-
Mouse Anti-ABCA3 Recombinant Antibody (V2-178911) (CBMAB-A0145-YC)
-
Mouse Anti-ACKR3 Recombinant Antibody (V2-261265) (CBMAB-C1023-LY)
-
Mouse Anti-CCN2 Recombinant Antibody (CBFYC-2383) (CBMAB-C2456-FY)
-
Mouse Anti-BIRC3 Recombinant Antibody (16E63) (CBMAB-C3367-LY)
-
Rabbit Anti-ADRA1A Recombinant Antibody (V2-12532) (CBMAB-1022-CN)
-
Mouse Anti-APCS Recombinant Antibody (CBYC-A663) (CBMAB-A3054-YC)
-
Rat Anti-4-1BB Recombinant Antibody (V2-1558) (CBMAB-0953-LY)
-
Rat Anti-(1-5)-α-L-Arabinan Recombinant Antibody (V2-501861) (CBMAB-XB0003-YC)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Rat Anti-CD34 Recombinant Antibody (MEC 14.7) (CBMAB-C10196-LY)
-
Mouse Anti-ARID3A Antibody (A4) (CBMAB-0128-YC)
-
Mouse Anti-GFAP Recombinant Antibody (24) (CBMAB-G2927-LY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0442) (CBMAB-0445-YY)
-
Mouse Anti-AKR1B1 Antibody (V2-2449) (CBMAB-1001CQ)
-
Mouse Anti-BACE1 Recombinant Antibody (61-3E7) (CBMAB-1183-CN)
-
Mouse Anti-ACE2 Recombinant Antibody (V2-179293) (CBMAB-A0566-YC)
-
Mouse Anti-ADGRE2 Recombinant Antibody (V2-261270) (CBMAB-C0813-LY)
-
Rat Anti-CCR2 Recombinant Antibody (475301) (CBMAB-C1338-LY)
-
Mouse Anti-ACLY Recombinant Antibody (V2-179314) (CBMAB-A0610-YC)
-
Mouse Anti-C4B Recombinant Antibody (CBYY-C2996) (CBMAB-C4439-YY)
Breast Cancer
Fig.1 Breast cancer
Breast cancer is mainly considered to develop in cells from the lining of milk ducts and the lobules that produce the milk, which is known as ductal carcinomas and lobular carcinomas. Risk factors giving rise to breast cancer include being female, obesity, lacking of physical exercise and so on. Signs of breast cancer may include a red scaly patch of skin, a lump in the breast, a change in breast shape, dimpling of the skin or fluid coming from the nipple. About 5–10% of cases can be attributed to genes inherited from a person's parents, including BRCA1 and BRCA2 among others. The diagnosis of breast cancer can be confirmed by taking a biopsy of the concerning lump. In addition, when the diagnosis is made, further tests need to be done to determine if the cancer has spread beyond the breast and which treatments it may respond to. Clinically, the most useful metabolic markers in breast cancer are the estrogen and progesterone receptors that are used to predict response to hormone therapy. HER-2 and SCD1 predict response to therapeutic regimens, and urokinase plasminogen activators (PA1-1 and SCD1) are used for assessing prognosis.
Products List
Loading...
Compare
